Alleviate Health, Backed by Andreessen Horowitz, Launches to Accelerate Patient Recruitment at Scale

Audio By Carbonatix

DURHAM, N.C.--(BUSINESS WIRE)--Oct 13, 2025--

Alleviate Health, the AI recruiter to accelerate patient recruitment for clinical research sites, today publicly launched their product and announced their $4.3M seed round led by Andreessen Horowitz. Alleviate is already working with 7 out of the top 15 site networks in the United States with customers including Alcanza, CenExel, M3 Wake, Centricity, Eximia and many others.

Clinical research sites, the backbone of clinical trial execution, are inundated with thousands of potential patients whom staff must call, qualify against protocol criteria, and coordinate through prescreening and scheduling across dozens of Sponsor and Site systems. This process of manual outreach, phone tag, and fragmented workflows slows recruitment, burns out teams, and delays trials.

Alleviate Health solves this bottleneck with human-in-the-loop AI agents that engage patients 24/7 across SMS and Voice, verify eligibility against protocols, and book visits and calls. Alleviate brings in recruitment teams at the right moments to preserve the human touch that is critical to clinical trials recruitment while automating the repetitive portions of the recruitment workflow – increasing efficiency by an order of magnitude. All of these interactions, along with patient preferences and medical data, are captured in a clinical-research specific CRM, purpose-built to help sites improve future recruitment and optimize the entire funnel.

“Research sites are the backbone of every clinical trial. They deserve technology built specifically for their needs and the patients they serve,” said Saathvik Boompelli, CEO & Co-founder of Alleviate Health. “Our customers, who juggle dozens of trials at once, are now able to do more with less while delivering a truly seamless experience for patients,” added John Xu, CTO & Co-founder of Alleviate Health.

Over the last year, Alleviate Health has supported 500k+ patient interactions across 190+ sites in the United States and Canada, helping sites accelerate recruitment across more than 300 unique trials.

“The impact that Alleviate has had on Alcanza’s recruitment function is incredible and one that I wouldn’t have believed when we first got started,” said Carlos Orantes, CEO of Alcanza Clinical Research. “Alleviate has enabled the scheduling of hundreds of on-site screening appointments not just at one site but at multiple sites across the entire Alcanza network during the past 10 months of working together.”

“As the teams on the ground drive trials forward, research sites need modern tools, purpose-built to turn interest into enrolled patients,” said Jay Rughani, investing partner at Andreessen Horowitz. “Alleviate gives research teams immense leverage – streamlining operations while improving the patient experience.”

In addition to Andreessen Horowitz, Jack Altman (Alt Capital), and Ali Rowghani (First Harmonic), other investors include Sajith Wickramasekara (Benchling), Trey Holterman (Tennr), Josh Miller (Gradient Health), Max Cohen (Sprinter Health), and Christophe Rimann (Camber).

To learn more about Alleviate Health, visit https://alleviatehealth.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251013052326/en/

CONTACT: Saathvik Boompelli

[email protected]

KEYWORD: NORTH CAROLINA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY MEDICAL DEVICES CLINICAL TRIALS HEALTH TECHNOLOGY SOFTWARE BIOTECHNOLOGY HEALTH PHARMACEUTICAL ARTIFICIAL INTELLIGENCE

SOURCE: Alleviate Health

Copyright Business Wire 2025.

PUB: 10/13/2025 09:00 AM/DISC: 10/13/2025 09:00 AM

http://www.businesswire.com/news/home/20251013052326/en